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Case presentation
A 42-year-old man was first evaluated in the Psychiatric Clinic
for increasingly frequent "manic" episodes during the past sev-
eral years. Each episode lasted several weeks, and the patient
had no clear evidence of depression. His medical history was
unremarkable, except for the alleged passage of a urinary stone
approximately 20 years previously. Physical examination was
normal. Initial laboratory studies revealed: serum creatinine, 1.2
mg/dl; BUN, 18 mg/dl; blood glucose, 110 mg/dl; sodium, 140
mEq/liter; carbon dioxide content, 29 mmollliter; and calcium,
8.9 mg/dl. Results of urinalysis (random specimen) revealed spe-
cific gravity, 1.028; pH, 5.0; no protein, glucose, or acetone were
evident. The urine sediment was not remarkable, and a urine cul-
ture revealed no growth. Hemogram and liver function tests
were normal. A chest x-ray and electrocardiogram were within
normal limits. An unknown dose of lithium carbonate was pre-
scribed, but the plasma lithium levels were determined. Six
months later, the plasma lithium level was 1.2 mEq/liter, and the
patient reported a marked decrease in his periodic hyperactivity.
Approximately 9 months after initiation of lithium therapy, the
patient's blood pressure was 155/95 mm Hg and he was treated
with a low-salt diet and a diuretic. Two weeks later he com-
plained of increasing lethargy, polyuna, and polydipsia. Physical
examination revealed a blood pressure of 144/88 mm Hg (which
dropped to 132/80 mm Hg upon standing), but was otherwise nor-
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mg/dl; BUN, 22 mg/dl blood glucose, 90 mg/dl; and lithium, 2.8
mEq/liter. Results of urinalysis (first morning specimen) revealed
specific gravity, 1.008; pH, 6.5; and a trace of protein but no
glucose or acetone. The urine sediment was unremarkable, Oth-
er laboratory tests were normal or unchanged. An overnight wa-
ter deprivation test (14 hours of water deprivation) revealed:
Uom, mOsm/kg POEm, mOsm/kg
345 302
400 310
The patient did not respond to administration of exogenous aque-
ous vasopressin (10 units). At the end of the deprivation test,
simultaneous venous and urinary pH values were 7.30 and 6.0,
respectively.
A diagnosis of mild lithium intoxication was made; the patient
was instructed to discontinue taking the diuretic and to omit lith-
ium therapy for the next 3 days. At follow-up 4 days later, the
patient felt less lethargic; his blood pressure was unchanged; the
plasma lithium concentration was 2.0 mEq/liter, and the sodium
was 144 mEq/liter, The patient was advised to resume his usual
lithium dose after another 3 days and to return for evaluation in
one month. At the follow-up examination one month later, the
patient felt well, his blood pressure was unchanged, and he re-
ported minimal polyuria and polydipsia.
When the patient returned for a second follow-up examination
6 months later, he reported increased lethargy and polydipsia
over the previous 2 months. Although he had not taken any di-
uretics, he had adhered to a low-salt diet. No changes were ap-
parent in his physical examination at that time. Laboratory stud-
ies revealed: BUN, 48 mg/dl; serum creatinine, 3.1 mg/dl; so-
dium, 146 mEq/liter; chloride, 108 mEq/liter; potassium, 3.2
mEq/liter; and carbon dioxide content, 24 mmol/liter. Results of
urinalysis revealed specific gravity, 1.010; pH, 6.0; and 1+ pro-
tein but no glucose or acetone; the urine sediment contained 0 to
2 white blood cells, 0 to 1 red blood cells, and 0 to 2 renal tubular
cells per high-power field. The plasma lithium concentration was
2.4 mEq/liter. The patient resumed a normal salt intake, and 2
weeks later he felt much better, with decreased lethargy and
polydipsia. His physical examination was entirely normal. On
repeat examination, the plasma lithium concentration was 1.1
mEq/liter.
The patient continued to feel well and returned 3 months later.
Physical examination was unchanged. Laboratory studies re-
vealed: BUN, 36 mg/dl; serum creatinine, 2.7 mg/dl; sodium, 144
mEq/liter; chloride, 106 mEq/liter; potassium, 3.8 mEq/liter; car-
bon dioxide content, 24 mmollliter; and lithium, 1.0 mEq/liter.
Results of urinalysis revealed specific gravity, 1.008; pH 6.0; a
trace of protein and no g1ucose or acetone. The urine sediment
contained 0 to 2 white blood cells and 0 to 2 renal tubular cells
per high-power field, with no red blood cells or casts. An abdom-
inal radiograph revealed two symmetrical kidneys of normal
size; ultrasonic examination disclosed no evidence of obstruc-
tion or any other abnormality; an intravenous urogram was nor-
before deprivation:
after deprivation:
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ma!. Repeat water deprivation testing, pH determinations, and
other laboratory studies were essentially unchanged. A 24-hour
urine specimen revealed SO mg calcium, 500 mg uric acid, and
200 mg protein. Six months later the patient remained asympto-
matic and physical examination was normal. Laboratory exami-
nation revealed: BUN, 38 mg/dl; serum creatinine, 2.8 mgldl;
lithium and other electrolyte concentrations were unchanged;
and the urinalysis was unchanged.
Discussion
DR. IRWIN SINGER (Chief, Medical Service,
Philadelphia Veterans Administration Medical
Center, and Professor of Medicine, University of
Pennsylvania School of Medicine, Philadelphia,
Pennsylvania): This patient illustrates most of the
important renal and electrolyte abnormalities asso-
ciated with the use of lithium in clinical practice.
The patient was an apparently healthy 42-year-old
man treated with a standard dose of lithium carbon-
ate for a psychiatric disturbance. The patient's his-
tory included a "stone" passed 20 years previously,
but he had had no recurrences and had a normal
laboratory evaluation prior to beginning lithium
therapy; thus, we can assume that the patient had
no underlying renal disease. His plasma lithium
concentration was in the therapeutic range 6
months after therapy was begun, and he had no
symptoms of lithium toxicity. About 3 months later,
however, in association with diuretic-induced so-
dium depletion, the patient did develop polyuria
and polydipsia, classic early symptoms of toxicity
from this substance. Evaluation at that time re-
vealed an antidiuretic hormone (ADH)-resistant uri-
nary concentrating defect in association with a dou-
bling of the plasma lithium concentration. In addi-
tion, findings of a borderline low venous pH without
a maximally acidic urine suggested a mild renal
acidification defect. The modest increases in BUN
and serum creatinine concentration might reflect
early renal damage from lithium, but these also could
be attributed to mild volume depletion (secondary
to the diuretic per Se, lithium-induced natriuresis,
lithium-induced nephrogenic diabetes insipidus, or
all three). The patient's symptoms abated when lith-
ium was briefly withheld and diuretics were discon-
tinued, but the patient never regained normal renal
function.
Lithium intoxication recurred the following sum-
mer, once again in a setting suggestive of mild so-
dium depletion. Although this episode seems super-
ficially similar to the previous one, some differences
are noteworthy. The plasma lithium concentration
was lower than in the previous episode, but the
BUN and serum creatinine were higher. In addi-
tion, the urinalysis revealed 1 + proteinuria and a
few cellular elements for the first time. These find-
ings suggest possible anatomic as well as functional
damage to the kidney. Since the patient's blood
pressure was normal throughout, and since no in-
dication of any other cause of renal damage was
present, the abnormalities in the urine sediment and
the proteinuria were probably due to lithium.
After sodium balance was restored and the
plasma lithium concentration returned to the thera-
peutic range, laboratory evaluation continued to re-
veal an elevated BUN and serum creatinine, and an
abnormal urine sediment. The abnormalities in the
urinary concentrating and acidifying abilities appar-
ently were unchanged. A 24-hour urine specimen
failed to disclose any abnormalities in calcium or
uric acid metabolism; the protein content was mini-
mally increased. No gross anatomic abnormalities
could be identified by radiographic or ultrasonic ex-
aminations. This combination of laboratory findings
is more suggestive of primary tubular or interstitial,
rather than glomerular or obstructive renal disease.
Nine months after the second episode of lithium in-
toxication, the BUN and serum creatinine concen-
tration were still elevated, and the urine sediment
was still abnormal; these findings confirm the pres-
ence of residual and possibly permanent renal dam-
age. The most likely cause for all of these abnormal-
ities is lithium-induced nephrotoxicity.
Lithium has many actions in humans and ani-
mals, and it affects several organ systems. This dis-
cussion will focus exclusively on the renal effects of
lithium, the primary manifestations of lithium tox-
icity in this patient. Two different kinds of nephro-
toxicity must be considered: one occurring in asso-
ciation with acute lithium intoxication and the other
in association with chronic therapy. Acute lithium
intoxication is primarily a central nervous system
syndrome, usually associated with high plasma lith-
ium concentrations. Patients with acute lithium in-
toxication often develop renal tubular disturbances
that are usually reversible. Chronic lithium nephro-
toxicity can occur with long-term exposure even
when lithium levels remain within the therapeutic
range; as with acute lithium nephrotoxicity, renal
tubular disturbances are common, but permanent
renal damage due to interstitial nephritis is an addi-
tional concern. Although the renal tubular defects,
particularly nephrogenic diabetes insipidus, have
been recognized for many years, the possible devel-
opment of permanent renal damage has been de-
scribed relatively recently. In the remainder of this
discussion, I will review the several functional renal
tubular defects associated with the use of lithium.
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Then I will ask Dr. Malcolm Cox to review in detail
the evidence suggesting that long-term therapy with
lithium produces chronic nephropathy in humans.
Effects of lithium on sodium balance. Therapeu-
tic concentrations of lithium alter sodium balance in
a characteristic fashion in humans: transient nat-
riuresis (lasting one or two days) is followed by a
period of sodium retention and probably a return to
the initial state of sodium balance [1—5] (Fig. 1).
There are no systematic studies of the effects of tox-
ic levels of lithium on sodium balance in humans,
but two patients with acute lithium intoxication did
have a natriuresis more marked than that observed
in patients with therapeutic serum levels of lithium
[6]. Lithium also has been shown to cause sodium
depletion in animals [6-15].
The nephron segments where lithium interferes
with sodium reabsorption have not been definitely
identified. Animal studies have suggested several
sites of lithium action. For example, since the prox-
imal tubule of the rat is the major nephron segment
that resorbs uric acid, and since lithium-induced
natriuresis in rats is accompanied by increased ex-
cretion of uric acid [13], the proximal tubule is pre-
sumed to be one site at which lithium exerts its in-
hibitory effect on sodium reabsorption. An action of
lithium in this segment also is supported by the ob-
servations that Brattleboro rats become more poly-
uric after treatment with lithium [12, 15], and that
the administration of lithium during a steady-state
E
>
water diuresis in Brattleboro rats causes a marked
increase in fractional electrolyte-free water clear-
ance [16]. Presumably, the inhibition of proximal
tubular sodium reabsorption results in increased de-
livery of fluid out of the proximal tubule to the as-
cending limb of Henle's loop and distal convoluted
tubule, and hence increases the generation of elec-
trolyte-free water.
The thick ascending limb can markedly increase
electrolyte-free water generation following in-
creased delivery of sodium and water in the pres-
ence of lithium; sodium chloride transport at this
site therefore cannot be grossly impaired by lith-
ium. Indeed, electrolyte-free water clearance is nor-
mal both in humans [17] and in experimental ani-
mals receiving therapeutic doses of lithium [13, 18].
In addition, lithium has little or no effect on the
maintenance of the normal corticopapillary gradient
for sodium [19-23]; this finding is another indication
that sodium reabsorption in the ascending limb is
grossly intact. Finally, micropuncture studies in
rats have shown that although the chronic adminis-
tration of lithium reduces proximal tubular sodium
reabsorption, reabsorption of sodium in the loop of
Henle is increased [24].
Despite increased sodium reabsorption by the
loop, a natriuresis still occurs [24], which probably
is due to decreased sodium reabsorption in the dis-
tal convoluted tubule, collecting duct, or both. This
conclusion also is supported by the observation that
lithium inhibits sodium transport in in vitro models
of the mammalian distal nephron, such as the toad
urinary bladder and frog skin [25-31]. Lithium
therefore appears to inhibit sodium reabsorption
more or less diffusely throughout the nephron, with
the possible exception of the thick ascending limb
of Henle's loop.
Lithium could cause natriuresis by several mech-
anisms. One such possibility is that lithium directly
competes with sodium for transport, as appears to
be the case in the toad urinary bladder and frog skin
[25—31]. Such a competition, however, has not been
demonstrated in humans. Another possibility is that
lithium interacts with one or more of the homeo-
static systems that control renal sodium reabsorp-
tion. Lithium does inhibit ADH-induced sodium
transport in the toad urinary bladder [17, 21, 28, 32,
33], but ADH probably does not have an important
direct effect on sodium reabsorption in mammals; it
thus appears unlikely that this mechanism accounts
for lithium-induced natriuresis in humans.
A third and more likely possibility is that the nat-
riuresis occurs because of an interaction of lithium
Control Lithium
Fig. 1. Effect of lithium administration on sodium excretion
(UNaV, mEqI24 hr) in 10 patients on constant (100 mEq) sodium
diets. (Reprinted with permission of J Psychiatr Res [5].)
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Fig. 2. Effect of lithium on the supine and standing plasma renin
activities and aldosterone concentrations in 7 patients with af-
fective psychiatric disorders. (Reprinted with permission ofAm J
Med [34].)
with the renin-angiotensin-aldosterone axis: lithium
could inhibit aldosterone production, release, or
both; or it could interfere with the tubular action of
aldosterone. Studies of the acute effects of lithium
on aldosterone production and release have pro-
vided conflicting results that are difficult to inter-
pret. In long-term studies of lithium-treated humans
and animals, however, plasma renin activity and
plasma aldosterone levels (or aldosterone excretory
or secretory rates) generally are normal, and these
hormones have been found to respond to stimuli in
an appropriate fashion [15, 34-36] (Fig. 2). Con-
sequently, lithium-induced natriuresis probably is
not secondary to reduced aldosterone secretion. In
contrast, the defective renal response to aldoste-
rone in rats treated with lithium [6, 37], and the inhi-
bition by lithium of aldosterone-induced sodium
transport in toad urinary bladders [38, 39], suggests
that the lithium-induced natriuresis might be due, in
part, to a relative unresponsiveness of the distal
nephron to aldosterone.
Although the fine details of renal tubular handling
of lithium are not completely understood, its rela-
tionship to sodium balance is well established: so-
dium depletion decreases, and sodium repletion in-
creases, the fractional excretion of lithium [5, 40—
49]. Consequently, if toxic lithium levels produced
a persistent or marked natriuresis and sodium de-
pletion, renal excretion of lithium would decrease.
This would lead to an increase in the serum lithium
concentration and to an aggravation of the natriure-
sis. That such a vicious cycle is actually involved in
the development of lithium toxicity is supported by
the observation that administration of sodium chlo-
ride to lithium-toxic animals diminishes or reverses
the toxicity [10, 11, 50, 51]. The findings in this pa-
tient are in keeping with this hypothesis: sodium de-
pletion precipitated his lithium intoxication, and so-
dium repletion reversed it.
The relationship between sodium balance and
fractional lithium excretion explains why the risk of
lithium intoxication is increased both in patients
eating low-sodium diets, and in patients treated
chronically with thiazide or other diuretics [5, 45,
52—63]. Consequently, if diuretics are employed ei-
ther to reduce polyuria in patients with lithium-in-
duced nephrogenic diabetes insipidus or for any
other purpose (for example, to treat "high blood
pressure," as in this patient), careful monitoring of
the serum lithium level is mandatory.
Effects of lithium on water balance. Although the
exact prevalence is unknown, polyuria and poly-
dipsia are common in lithium-treated patients; esti-
mates range from 20% to 70% [22, 63-67]. In gener-
al, little correlation exists between serum lithium
levels and the severity of the polyuria; many poly-
uric patients have lithium levels within the thera-
peutic range.
Lithium-induced polydipsia and polyuria could
be due to primary polydipsia with secondary poly-
uria, to primary polyuria with secondary poly-
dipsia, or to a combination of both [68]. Although
lithium is thought to stimulate thirst in rats [14, 69—
71], lithium-induced primary polydipsia does not
appear to have an important role in the genesis of
the polyuria in humans [22, 34, 67].
In evaluating a primary defect in renal water con-
servation, we must consider the potential sites of
action of lithium. Lithium could interfere with: (1)
the synthesis or release of ADH from the hypotha-
lamic-pituitary axis (central diabetes insipidus); (2)
the production or maintenance of medullary hyper-
tonicity; and (3) the renal tubular action of ADH
(nephrogenic diabetes insipidus). Lithium-induced
polyuria is characterized by normal free-water gen-
eration and impaired free-water reabsorption [13,
17, 18]. These findings strongly suggest that lithium
exerts its primary effect by interfering with the
ADH-dependent aspects of water homeostasis (that
is, by producing central or nephrogenic diabetes in-
sipidus).
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When directly measured, urinary and plasma
ADH levels generally are either normal or elevated
during lithium administration [15, 34, 58, 66, 67, 72]
(Fig. 3), and lithium has no effect on the release of
ADH by isolated rat pituitary glands [73]. Although
some evidence indicates that lithium-induced inhi-
bition of ADH release occasionally might contrib-
ute to lithium-induced polyuria [17, 22], only a
single well-documented case of lithium-induced
central diabetes insipidus has been described to
date [67] (Fig. 3). Thus lithium-induced central dia-
betes insipidus is probably very uncommon.
The glomerular filtration rate is normal during
lithium-induced polyuria [5, 10, 13, 17, 19, 74], and
lithium does not grossly alter either the medullary
concentration of urea [21] or the normal corticopap-
illary sodium gradient [19—22, 75]; it seems unlikely
therefore that lithium has a clinically significant ef-
fect on the maintenance of medullary hypertonicity.
Lithium-induced nephrogenic diabetes insipidus
is clearly the major cause of lithium-induced poly-
uria, both in humans and in animals [12, 17, 21-23,
58, 75-77]. This conclusion was elegantly confirmed
in a group of 17 patients receiving lithium mainte-
nance therapy [67]; the majority of these patients
had elevated plasma ADH levels and relatively low
urine osmolalities (Fig. 3). Lithium also has been
shown to impair ADH-induced increases in osmotic
water flow in the toad urinary bladder [17, 21, 33].
Although the mechanisms by which lithium pro-
duces nephrogenic diabetes insipidus are not entire-
ly clear in all species, substantial evidence suggests
that lithium interferes with the cellular action of
ADH at points both proximal and distal to the
ADH-induced generation of cyclic AMP in renal
epithelia [17, 21, 33, 68, 78, 79].
Effects of lithium on acid-base balance. Lithium
can produce a urinary acidification defect in animals
[80, 81] and in humans [34, 82, 83]. For example, 7
of 15 patients [82] and 5 of 6 patients [34] receiving
maintenance lithium therapy were unable to acidify
their urine normally during acid loading. The frac-
tional excretion of bicarbonate (at normal plasma
bicarbonate concentrations) was relatively small,
and the urinary excretion of phosphate and am-
monia was normal; therefore, the urinary acid-
ification defect is not due to proximal (bicarbonate-
wasting) renal tubular acidosis or to a reduction in
urinary buffering capacity. By exclusion, the acid-
ification defect can be ascribed to distal renal tubu-
lar acidosis [84], and since none of the patients was
acidemic, the renal tubular acidosis is of the in-
complete variety.
Fig. 3. Relation bet wee,i urine osmolalit and plasma vasopres-
sin concentration in 17 patients with low urine os,nolalit.
Shaded area represents the 95% confidence limits of control
data. LD = limit of detection. (Reprinted with permission of
Ann Intern Med [67].)
There are no apparent reasons why only one-half
of the patients studied by Perez et al were affected
[82]. The serum lithium concentrations were in the
therapeutic range in all patients, and the lithium lev-
els in those who developed renal tubular acidosis
were not different from those who did not. Since
none of the patients was acidemic on a regular diet,
lithium-induced distal renal tubular acidosis might
not be clinically important. However, when
stressed by an endogenous or exogenous acid load,
such patients might have a diminished capacity to
preserve acid-base homeostasis. The mild decrease
in plasma carbon dioxide content and the inability
of today's patient to maximally acidify the urine
probably can be attributed to lithium, although no
additional acid load could be identified.
Lithium-induced nephrotic syndrome. Several re-
cent case reports have described the development
of nephrotic syndrome in association with chronic
lithium administration [85-87]. Plasma lithium lev-
els were in the therapeutic range in all patients, and
no patient had renal insufficiency. Renal biopsies in
2 patients revealed typical findings of "lipoid ne-
phrosis," or minimal change disease. In both cases,
the proteinuria resolved when lithium was discon-
tinued; in one patient it recurred when lithium was
reinstituted. The mechanism for the proteinuria is
not known. The proteinuria in the patient we are
discussing was not in the nephrotic range but prob-
ably was related to the lithium therapy.
Lithium-induced acute renal failure. Scattered
reports have appeared linking lithium with renal
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morphologic changes suggestive of acute tubular
necrosis. Animal studies have indicated that the po-
tential for such lithium-induced damage clearly ex-
ists [7, 88, 89]. Proximal tubular damage has been
noted in 2 lithium-intoxicated patients [90, 91], and
necrosis of the distal nephron has been noted in sev-
eral patients with therapeutic lithium levels [92, 93].
In contrast, other investigators have found little or
no evidence of acute renal histopathologic changes
in humans that could be ascribed to lithium per se
[94—99]. The case for therapeutic levels of lithium
directly producing histopathologic changes of a
type analogous to acute tubular necrosis in humans
has yet to be made; furthermore, in severely lith-
ium-intoxicated patients, it is possible that other ef-
fects of lithium (such as circUlatory collapse) might
produce acute tubular necrosis.
Questions and answers
DR. JORDAN J. COHEN: Dr. Cox, you recently
had an opportunity to review the evidence in-
criminating lithium therapy as a cause of chronic
renal insufficiency. Would you share your thoughts
about this important question with us?
DR. MALCOLM Cox (Renal Electrolyte Section,
Medical Service, Philadelphia Veterans Adminis-
tration Medical Center, and Assistant Professor of
Medicine, University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania): Whether
maintenance lithium therapy, with or without inter-
mittent episodes of intoxication, is associated with
progressive renal insufficiency is indeed an impor-
tant question given the large number of patients cur-
rently receiving lithium. Studies of renal function in
relation to lithium therapy have measured both re-
nal concentrating ability after lithium use has been
discontinued and the glomerular filtration rate dur-
ing maintenance lithium therapy. Morphologic stud-
ies only rarely have been correlated with functional
studies, and generally these have been limited to
light microscopy.
The concentrating defect produced by lithium
generally had been considered readily reversible
when use of the drug was discontinued. More re-
cently, however, the concentrating defect has been
found to persist for months or years following ces-
sation of therapy [79, 100-103]. The persistence of a
concentrating defect suggests that maintenance lith-
ium therapy might, at least in some patients, lead to
long-term functional renal damage. The incidence
of a persistent defect in renal concentrating ability
is unknown, however, and prospective studies of
larger numbers of patients are needed to clarify this
issue.
The initial concern that lithium might cause pro-
gressive morphologic renal disease and renal in-
sufficiency arose from the results of renal biopsies
performed in 14 patients who had received lithium
for 2 to 14 years [96]. Thirteen of the 14 biopsy
specimens demonstrated focal nephron atrophy,
marked interstitial fibrosis, or both when compared
with similar material from age-matched normal sub-
jects. The authors concluded that routine mainte-
nance therapy with lithium might produce progres-
sive interstitial nephritis. In my opinion, several
limitations of this study preclude such a firm con-
clusion. First, the study patients were selected from
a larger population because they had had an acute
episode of lithium intoxication, had severe poly-
uria, or both. It is unclear whether the average, un-
intoxicated patient receiving lithium would develop
the same morphologic changes. Second, since pa-
tients with severe psychiatric illnesses might be at
greater risk for developing renal disease than are
normal individuals, [99], the normal control group
used in this study is inappropriate; a similar group
of patients with comparable psychiatric disorders
who were not treated with lithium would have pro-
vided a more valuable control. Third, since the his-
topathologic changes observed are completely non-
specific, the chronic interstitial nephritis in these
patients cannot be ascribed with certainty to lithium
per Se. Finally, preexisting interstitial nephritis can-
not be definitively excluded in these patients be-
cause virtually the only information concerning
renal function available prior to the institution of
lithium therapy was the serum creatinine concen-
tration, which is unreliable as an indicator of early
interstitial nephritis.
In a second study by the same group, 32 of 110
patients who had received lithium for 6 months or
more were found to have either polyuria (> 3000 mlJ
day) or a decreased GFR (arbitrarily defined on the
basis of age) [97]. Of the 32 patients, 18 were
thought to have had lithium-induced nephropathy
because no evidence for other types of renal disease
was apparent. The mean age of these 18 patients
was 48 years, and all had taken lithium for at least 2
years. All 18 had concentrating defects (Umax <800
mOsmlkg after dehydration), but no information
was provided about how many of the patients had
discontinued taking lithium prior to the study; it is
difficult, therefore, to determine whether the con-
centrating defects were indicative of underlying
persistent functional or morphologic changes. The
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mean creatinine clearance of the 18 patients at the
time of the study was 85 mllmin, but since the GFR
in an appropriate age-matched control group was
not provided, this information is also difficult to in-
terpret. The serum creatinine concentrations (mean
1 SD) prior to institution of lithium therapy and at
the time of the study were 1.07 0.13 (range, 0.8 to
1.3) and 1.33 0.31 (range, 0.9 to 2.0) mg/dl, re-
spectively. This small increase in serum creatinine
could be due to the development of lithium-induced
renal disease, but it also could be explained in a va-
riety of other ways, such as volume depletion sec-
ondary to lithium-induced natriuresis or nephrogen-
ic diabetes insipidus. Renal biopsy in 14 of the 18
patients showed the same nonspecific lesions pre-
viously described [96].
In another study, Burrows et al reported histo-
pathologic changes in renal biopsies from 5 patients
who had received lithium for 4 months to 9 years
[93]. All biopsies showed ballooning, vacuolization,
prominent PAS-positive staining, and necrosis in
the distal convoluted tubules and collecting ducts.
In addition, 3 of the patients (who had taken lithium
for 6, 7, and 9 years) had evidence of chronic inter-
stitial nephritis. The authors suggested that the
tubular lesions, particularly the presence of PAS-
positive material, were a unique and specific in-
dication of lithium-induced renal injury, and that
these lesions represented an early stage of the proc-
ess that ultimately progresses to chronic interstitial
nephritis. However, the presence of PAS-positive
material in renal biopsies is nonspecific [104], and
because the patients had been treated with a variety
of other psychotropic medications, it is difficult to
incriminate lithium as the sole offending agent in
this study.
A subsequent report by the same investigators
[99] casts further doubt on the conclusions derived
from the morphologic studies of Hestbech et al [96,
97]. Renal biopsies in 16 patients who had been
treated with lithium for a mean of 5.5 years were
compared both with biopsies obtained from a group
of 9 psychiatric patients preparing to start lithium
treatment, and with biopsies obtained from a group
of age-matched normal kidney donors. Nonspecific
interstitial fibrosis was present in equal degrees in
both the lithium-treated patients and the patients
about to start lithium therapy; such changes were
not found in the kidneys obtained from the normal
subjects. These findings emphasize that patients
with severe psychiatric illnesses might be at greater
risk for developing renal disease than is the normal
population and point out the importance of using
appropriate control groups.
Results from several other recent studies of lith-
ium-induced nephropathy are shown in Table 1 [98,
105-110]. Preliminary data in 37 patients on mainte-
nance lithium therapy for 1 to 15 years revealed 6
patients with chronic interstitial fibrosis on renal
biopsy, 5 of whom had either polyuria (> 4000 ml!
day), decreased creatinine clearance (< 60 mllmin),
or both [981. The patients who had received lithium
for more than 10 years had the same prevalence of
abnormal findings as did the 5- to 10-year group.
Even assuming that the abnormalities were attribut-
able to lithium, their frequency appears to be less
than that reported previously [93, 96].
Vestergaard et al evaluated renal function in 237
patients on maintenance lithium therapy for 0.5 to
17 years (mean 5 years) [1051. In 218 patients with
satisfactory urine collections, the mean creatinine
clearance was 102 mllmin; only 15 patients had
clearances less than 70 mllmin. There was no corre-
Table 1. Lithium-induced chronic renal insufficiencya
Study [Ret]
Renal
Insufficiency
# pts %t
Anatomic
Abnormalities
# pis %
Hestbech [96] 14 50 (S) 14 93 (N)
Hansen[97] 110 16(N) 14 100(N)
Burrows [93] — — 5 100 (N)
Kincaid-Smith [99] —. — 16 0 (P)'
Rafaelson [98] 37 13 (N) 37 16(N)
Vestergaard [105]
218 7(N)
184 lI(S)
— —
Hallgren [106] 66 10(N) — —
.Hullin [1071
106 5(N)
30 0(P)
— —
Donker [108] 30 3 (N) — —
MUller-
Oerlinghausen[109] 40 0(S) — —
Colt[110] 140 8(S) — —
a This table summarizes the major available studies on lithium-
induced chronic renal insufficiency. Many differences exist
among the various studies regarding the nature of the controls,
the definitions of renal insufficiency, and the inclusion or ex-
clusion of patients with other potential causes of renal disease.
Consequently, the data should be considered approximate.
b i% refers to the percentage difference between patients and
controls.
S refers to self control, i.e., pre- and post-lithium.
dN refers to normal subjects or no controls.
° P refers to other psychiatric controls (patients not receiving
lithium).
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lation between creatinine clearance and duration of
treatment. Pretreatment serum creatinine concen-
trations were available in 184 of these 237 patients
and were compared with the values obtained at the
time of the study. The mean serum creatinine in-
creased from 0.94 to 1.08 mg/dl. A significant rela-
tionship was found between the serum creatinine
concentration and duration of treatment. In 21 of
184 patients in whom pretreatment serum creatinine
concentrations were available, the serum creatinine
increased by more than 0.3 mg/dl; the highest value
was 2.0 mg/dl. These patients had received lithium
for a longer period (7.4 years) than had the remain-
der of the patients (4.5 years). Polyuria (> 3000 ml!
day) also was common in these patients. Standard
dehydration tests were performed in 31 of the 91
patients who had creatinine clearances less than 70
ml/minute and/or polyuria; 24 of the 31 had a Umax
less than 800 mOsm!kg. Drawing conclusions from
this study presents several problems. The small
decrement in GFR might have represented changes
in only a small group of patients and might not have
been a general trend. In addition, one does not
know whether these changes were lithium-induced.
This study does suggest, however, that in a relative-
ly large population treated with lithium for several
years, there was little evidence of a clinically impor-
tant decrement in renal function.
Haligren et al studied 66 patients taking lithium
from 2 months to 15 years [106]. Thirteen patients
had abnormalities: the GFR was decreased in 7 (but
only minimally in 5), albuminuria was present in 4,
and J32-microglobulinuria was present in 4. No cor-
relation existed between the GFR and the duration
of lithium therapy. However, 4 of the 13 patients
with abnormalities had evidence of preexisting re-
nal disease prior to the initiation of lithium therapy.
Hullin et al studied 106 patients on maintenance
lithium therapy [107]. A representative sample of 30
of these patients, who had received lithium for 3 to
12 years with the mean being 8 years, was com-
pared with an age- and sex-matched group of 30
psychiatric patients who had never received lith-
ium, but who were taking other psychotropic
agents. No significant differences in plasma creati-
nine concentration, creatinine clearance, Umax or
f32-microglobulin excretion were noted. These find-
ings, obtained with appropriate controls, do not
support the contention that chronic lithium therapy
results in renal damage. However, the authors
pointed out that the lithium administered to their
patients produced somewhat lower plasma levels
than is customary. Donker et al, who evaluated 30
patients on maintenance lithium therapy for 4 to 76
months, found the mean GFR to be 101 mllminute
and saw no correlation between the GFR and dura-
tion of therapy [108]. The mean Umax for the entire
group of patients was 854 mOsmlkg (range, 525 to
1078 mOsm!kg), and no correlation existed between
Umax and duration of therapy. Urinary /32-micro-
globulin excretion was normal in all patients.
Müller-Oerlinghausen and Drescher found no
change in the serum creatinine concentrations of 40
patients treated with lithium for 3 years [109]. Colt
et al found that only 11 of 140 lithium-treated pa-
tients had serum creatinine concentrations greater
than 1.5 mgfdl (mean, 1.7 mg/dl; highest value, 2.3
mg/dl) [1101.
As you can see, the results conflict. Because
these studies differ so much in design, patient selec-
tion, and definitions of abnormality, they are diffi-
cult to compare. It seems clear, however, that the
incidence of chronic interstitial nephritis and renal
insufficiency in patients on maintenance lithium
therapy is relatively low, and that the case support-
ing a role for lithium itself producing these abnor-
malities is weak. All of the studies published to date
have been retrospective and cross-sectional in de-
sign; in most, appropriate control groups have not
been employed. In fact, the only two studies that
have employed control groups composed of psychi-
attic patients not exposed to lithium failed to detect
differences between lithium-treated and control
subjects [99, 107]. The majority of the studies have
provided only fragmentary data on renal function
prior to the initiation of lithium therapy, and pre-
existing renal disease cannot be definitively ex-
cluded. In addition, since other causes of interstitial
nephritis during the period of lithium therapy were
not definitively excluded, the reported abnormal-
ities might have been due to coincidental causes
rather than to lithium per se. Finally, since lithium-
treated patients might have reductions in GFR be-
cause of sodium or water depletion, one cannot as-
sume that a low GFR represents underlying renal
disease unless volume depletion is ruled out.
Decisions about initiating maintenance lithium
therapy should include consideration of lithium's
possible nephrotoxic effects. However, it is well to
remember that manic-depressive illness has a sub-
stantial morbidity and mortality. Since available
studies suggest that, at worst, only a small minority
of patients treated with lithium develop renal in-
sufficiency, concern about renal toxicity should not
preclude the use of lithium in any patient who might
be expected to derive significant benefit from the
chronic administration of this effective psycho-
therapeutic agent.
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DR. COHEN: Dr. Shader, I am sure that Dr. Cox's
conclusion is as reassuring for you as it is for the
nephrologists in the audience. Would you care to
comment?
DR. RECHARD I. SHADER (Professor and Chair-
man, Department of Psychiatry, Tufts University
School of Medicine, and Psychiatrist-in-Chief,
NEMCH): I would like to congratulate you both on
a very informative and excellent presentation. As a
clinician and psychiatrist, however, I am disturbed
by your reference to a patient being placed on a
"standard" dose. We have come to learn, particu-
larly over the last 5 years, that there is great varia-
bility in dosage requirements because of factors
such as sex, age, race, and the phase of rnanic-de-
pressive disease. For example, the dose of lithium
required to treat a premenstrual depression is quite
different from the dose required to treat manic-de-
pressive illness or a recurrent unipolar depression.
In evaluating today's patient, I would find it helpful
to know what dosage of lithium the patient was tak-
ing at various times. Also, no mention was made of
the type of diuretic; the protocol merely states that
the patient was given a diuretic. Our clinical experi-
ence, as well as other laboratory research, indicates
that there might well be a difference in the potentia-
tion of lithium toxicity depending on whether the
diuretic is a potassium-sparing agent. Lithium tox-
icity might be based not so much on what happens
to sodium but on the differences in intracellular re-
placement of potassium by lithium.
DR. SINGER: We do not know which diuretic was
used in this patient. His "hypertension" was de-
tected in a screening program elsewhere, and he
was given an unknown diuretic. The interaction of
lithium with the potassium-sparing diuretics tn-
amterene and amiloride have been evaluated in vi-
tro [33]. The effects of lithium on sodium transport
in the toad urinary bladder are blocked by those di-
uretics; this action suggests that the diuretics inter-
fere with the absorption or the action of lithium.
Thus, I think that your clinical observations are
supported by laboratory studies.
DR. SHADER: My other questions are specula-
tions of a different sort. I am often asked whether,
in the early phases of lithium-induced polyunia and
polydipsia, water restriction (that is, the physician's
insistence that in response to the polydipsic drive
the patient take in less water) really has any benefi-
cial or harmful effect on what happens. Have you
any observations about that?
DR. SINGER: It has been my experience that when
these patients are water restricted, they get worse,
not better. They become more volume depleted,
their lithium levels rise, and they become uncom-
fortable.
DR. SHADER: I think that is an important point
because our clinical experience was the same, but
we had no real substantiation.
I also wanted to note that psychiatric patients
might have more underlying renal pathology, such
as interstitial fibrosis, than occurs in the general
population. It seems to me that histories from psy-
chiatric patients disclose remarkable use of aspirin
and other analgesics. Clinicians should try to docu-
ment the intake of agents that induce analgesic-
abuse nephropathy, which results in similar inter-
stitial renal damage [1111. Lithium intoxication
might be causing us needless worry; the subject
causes much concern, and I wish we could settle
the question of analgesic effect before we spend
much more time in the area.
DR. SINGER: Clearly, the incidence of analgesic-
abuse nephropathy is grossly underestimated. It is
not easy to obtain such a history even in a non-
psychiatric population. In addition, the list of other
agents that cause interstitial nephropathy seems to
expand every month. It is not just the analgesics,
but all of the other potential toxins and allergens
that preclude us from blaming nephropathy on a
particular agent; certainly your point is well taken.
DR. COHEN: Are there any animal models of in-
terstitial nephritis due to lithium administration?
DR. Cox: Hestbech has claimed that the adminis-
tration of large doses of lithium to rats for 9 weeks
produces interstitial fibrosis of a nature similar to
that observed in humans [112]. However, since rats
are known to develop identical lesions with advan-
cing age, the fibrotic changes cannot definitively be
ascribed to lithium. Indeed, Birch was unable to de-
termine in a blind fashion which kidneys came from
lithium-treated and which came from control ani-
mals [113]. Consequently, I do not think that any
good animal models are presently available.
DR. JEROME P. KASSIRER: I am curious about the
patient under discussion today. Initially, his serum
creatinine level was 1.2 mg/dl, and on the latest fol-
low-up, the serum creatinine was 2.8 mg/dl. Would
you speculate on the cause of renal insufficiency in
this particular patient?
DR. Cox: There is no doubt that the serum creati-
nine concentration increased significantly in this pa-
tient. It is also clear that the patient was not volume
depleted at the time that the elevated plasma creati-
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nine concentration was obtained. So I think one has
to conclude that this patient developed renal in-
sufficiency while taking lithium. This should not be
taken to mean that lithium was the cause of the re-
nal insufficiency, however. As discussed earlier,
there are a wide variety of causes of interstitial
nephritis; perhaps this patient was a surreptitious
analgesic abuser or perhaps the stone disease
played a role. Since there are many causes of inter-
stitial nephritis, it is difficult to incriminate a single
agent, lithium, as the cause of our patient's renal
disease. Unless prospective studies are done on
large numbers of patients (with careful attention to
histories of drug usage and periodic evaluations of
renal function), we are never going to know the an-
swer to this question because the incidence of lith-
ium-induced renal insufficiency is low. It might not
be nonexistent, but it is low; consequently, cross-
sectional studies are unlikely to provide definitive
answers.
DR. KASSIRER: Is there any evidence that lithium
produces enough renal damage to cause end-stage
renal failure?
DR. Cox: This appears to be extremely rare, if it
occurs at all. In the studies described [93, 96—99,
105—110], even those patients with presumed lith-
ium-induced renal disease had only mild degrees of
renal insufficiency. I know of only one case report
in which lithium was implicated as a cause of
marked chronic renal failure [114].
DR. SHADER: I only know personally of one pa-
tient, who I doubt is in the literature. His serum
creatinine concentration rose from 2.0 to 5.0 mgldl
over a period of about one year during which he
used lithium. Lithium use was the only apparent ex-
planation for his renal functional deterioration.
DR. SINGER: At least two other agents were un-
covered in this patient that ordinarily are ignored as
potential causes of renal damage: one is the un-
known diuretic; the second is the radiopaque medi-
um used during the intravenous pyelogram. Both of
these agents can elicit nephropathy. Furthermore,
some patients trade drugs to their friends, so that
patients might be taking drugs meant for their room-
mates, neighbors, or other clinic patients. Unless
one is prepared to perform drug screening on all of
these patients, I cannot incriminate lithium as the
sole nephrotoxic agent.
DR. KASSIRER: Do normal individuals adapted to
low-salt diets have increases in sodium excretion
when given lithium? In the data you showed, the
sodium intake was 100 mEq.
DR. SINGER: That has not been formally investi-
gated. Lithium was orginally introduced as a so-
dium substitute for patients with congestive heart
failure on the rationale that it would prevent edema.
Instead, these patients developed substantial lith-
ium toxicity, but I am not aware that the effects on
sodium excretion were examined then. I know of no
recent study of sodium excretion on a low-salt diet
in lithium-treated patients.
DR. KENNETH S. SHAPIRO (Renal Fellow,
NEMCH): Dr. Cox, in your review of the literature,
did you find any association between clinical lith-
ium intoxication and the development of pathologic
lesions? As I recall, Hestbech's study reviewed the
biopsies of patients who manifested acute lithium
intoxication and those who did not [96]. He was un-
able to distinguish any difference between the
biopsy findings in the two groups.
DR. Cox: That is not an easy question to answer.
You are absolutely right as far as Hestbach' s study
is concerned. The later studies appear to contain
lesser numbers of patients with overt lithium intoxi-
cation, but most of these studies do not include suf-
ficient clinical information to allow us absolute cer-
tainty of this. Whether the renal disease is depen-
dent on repeated episodes of lithium intoxication or
whether well-controlled maintenance lithium thera-
py without episodes of intoxication produces renal
disease is unclear from the information available.
DR. ANDREW LEVEY (Renal Fellow, NEMCH,):
You showed that the defect in water reabsorption
persisted in 3 of your patients 6 months after the
withdrawal of lithium. Is this defect permanent?
Did these patients have elevated serum creatinine
levels?
DR. SINGER: Yes, at least for many months. We
do not know whether the defect would have re-
solved over a longer period. In a large number of
patients, the defect abates in a matter of a few days
to a few weeks; only a minority of patients have
persistent defects. Whether their renal tubular func-
tion will eventually return to normal if one waits
long enough is unknown. It is hard to know when
body stores of lithium are reduced to zero because
lithium is predominantly intracellular in location.
When the plasma lithium level is reduced to near
zero by dialysis, the lithium level can rebound to
therapeutic levels several hours after the dialysis
ends because of transcellular shifts of lithium.
DR. COHEN: Dr. Shader, how well does the
plasma lithium level correlate with the psychiatric
response?
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DR. SHADER: There seems to be a therapeutic
'window," some minimum critical level that is es-
sential, but it isn't clear whether a linear dose-re-
sponse relationship exists within that window. As
clinical experience has accumulated, the therapeu-
tic ranges are becoming lower and lower: many pa-
tients improve at levels of 0.5 to 0.6 mEq/liter. The
old range of 0.75 to 1.5 mEq/liter no longer seems
appropriate, yet there are clear examples of patients
who totally fail to respond to levels lower than 1.5
to 2.0 mEq/liter. In such instances, I think one
treads on very dangerous ground; one should re-
member that lithium is not the only treatment for
this disease. When we treat a patient in whom lith-
ium therapy was discontinued because of an ele-
vated serum creatinine level, we have to wonder
why lithium was chosen as the continuing treatment
and why no other approach was attempted. This pa-
tient was described as only having repeated epi-
sodes of mania in the absence of depression. Typi-
cally, recurrent manic patients respond to other
forms of treatment such as neuroleptic (antipsy-
chotic) agents.
DR. SINGER: I don't think one should be too con-
fident of the plasma level as an index of lithium's
effects. If you believe that lithium works inside the
cell, the plasma level is only going to be roughly
correlated with the intracellular level, which can
vary from individual to individual and from tissue to
tissue. Physiologic effects of lithium also are subject
to changes in sodium and potassium balance as well
as a number of other metabolic processes.
Acknowledgment
We express our appreciation to Ms. K. Conrad
for secretarial assistance.
Reprint requests to Dr. Irwin Singer, Philadelphia Veterans
Administration Medical Center, University & Woodland Ave-
nues, Philadelphia, Pennsylvania 19104, USA
References
1. TRAUTNER EM, Moiuus R, NOACK CH, GERSHON S: The
excretion and retention of ingested lithium and its effect on
the ionic balance of man. Med J Aust 42:280—291, 1955
2. HULLIN RP, SWINSCOE JC, MCDONALD R, DRANSFIELD
GA: Metabolic balance studies on the effect of lithium salts
in manic-depressive psychosis. Br J Psychiatry 114:1561—
1573, 1968
3. MURPHY DL, GooDwIN FK, BUNNEY WE: Aldosterone
and sodium response to lithium administration in man. Lan-
cet 2:458—461, 1969
4. ARONOFF MS, EVENS RG, DURELL J: Effect of lithium salts
on electrolyte metabolism. J Psychiatr Res 8:139—159, 1971
5. BAER L, PLATMAN SR. KASSIR S, FIEVE RR: Mechanisms
of renal lithium handling and their relationship to mineral-
ocorticoids: A dissociation between sodium and lithium
ions.JPsychiatrRes 8:91—105, 1971
6. BAER L, GLASSMAN AH, KAs5IR S: Negative sodium bal-
ance in lithium carbonate toxicity. Evidence of mineral-
ocorticoid blockade. Arch Gen Psychiatry 29:823-827, 1973
7. RADOMSKI JL, FUYAT HN, NELSON AA, SMITH PK: The
toxic effects, excretion and distribution of lithium chloride.
JPharmacolExp Ther 100:429-444, 1950
8. SCHOU M: Lithium studies. II. Renal elimination. Acta
Pharmacol Toxicol (Copenh) 15:85-98, 1958
9. BAER L, KASSIR S. FIEVE RR: Lithium-induced changes in
electrolyte balance and tissue electrolyte concentration.
Psychopharmacologia 17:216—224, 1970
10. THOMSEN K: The effect of sodium chloride on kidney func-
tion in rats with lithium intoxication. Acta Pharmacol Tox-
icol (Copenh) 33:92—102, 1973
11. THOMSEN K, JENSEN J, OLESEN OV: Lithium-induced loss
of body sodium and the development of severe intoxication
in rats, Acta Pharmacol Toxicol (Copenh) 35:337—346, 1974
12. HOCHMAN S, GUTMAN Y: Lithium: ADH antagonism and
ADH independent action in rats with diabetes insipidus.
EarJ Pharmacol 28:100—107, 1974
13. MARTINEZ-MALDONADO M, STAVROULAKI-TSAPARA A,
TSAPARAS N, SUKI WN, EKNOYAN G: Renal effects of lith-
ium in rats: Alterations in water and electrolyte metabo-
lism and the response to vasopressin and cyclic adenosine
monophosphate during prolonged administration. J Lab
Clin Med 86:445-461, 1975
14. GALLA JN, FORREST JN, HECHT B, KASHGARIAN M, HAY-
SLETT JP: Effect of lithium on water and electrolyte metab-
olism, Yale JBiol Med 48:305—314, 1975
15. BALMENT Ri, JONES IC, HENDERSON 1W: Time course of
lithium-induced alterations in renal and endocrine function
in normal and Brattleboro rats with hypothalamic diabetes
insipidus. Br J Pharmacol 59:627—634. 1977
16. RAHN DW, FORREST JN JR: Lithium-enhancement of water
excretion in the absence of vasopressin. Clin Res 23:602A,
1975
17. SINGER I, ROTENBERG D, PUSCHETT JB: Lithium-induced
nephrogenic diabetes insipidus: in vivo and in vitro studies.
J Clin Invest 51:1081—1091, 1972
18. WEBB RK, WOODHALL PB, TISHER CC, ROBINSON RR:
Acute effects of lithium on the renal concentrating mecha-
nism in a primate. Am J Physiol 228:909—914, 1975
19. THOMSEN K: Lithium-induced polyuria in rats. mt Pharma-
copsychiatry 5:233—241, 1970
20. SOLOMON 5: Action of alkali metals on papillary-cortical
sodium gradient of dog kidney. Proc Soc Exp Biol Med
125:1183—1186, 1967
21. HARRIS CA, JENNER FA: Some aspects of the inhibition of
the action of antidiuretic hormone by lithium ions in the rat
kidney and bladder of the toad, Bufo marinas. Br J Phar-
macol 44:223—232, 1972
22. FORREST JN JR. COHEN AD, TORRETTI J, HIMMELHOCH
JM, EPSTEIN FH: On the mechanism of lithium-induced di-
abetes insipidus in man and the rat. J Clin Invest 53:1115—
1123, 1974
23. JENNER FA, MACNEIL 5: The effects of lithium ions on the
antidiuretic action of vasopressin in the rat. BrJPharmacol
55:527—534, 1975
Lithium and the kidney 385
24. HECHT B, KASHGARIAN M, FORREST JN, HAYSLETT JP
Effects of lithium on proximal and distal tubular function.
Clin Res 24:402A, 1976
25. HANSEN HH, ZERAHN K: Concentration of lithium, sodium
and potassium in epithelial cells of the isolated frog skin
during active transport of lithium. Acta Physiol Scand
60:189—196, 1964
26. NATOCHIN YV, LEONTEV VG: Pituitrin stimulation of ac-
tive transport of lithium by wall of frog urinary bladder.
Fiziol Zh SSSR 50:618-622, 1964
27. BIBER TUL, CURRAN PF: Direct measurements of uptake
of sodium at the outer surface of the frog skin. J Gen
Physiol 56:83-99, 1970
28. HERRERA FC, EGEA R, HERRERA AM: Movement of lith-
ium across toad urinary bladder. Am J Physiol 220:1501-
1508, 1971
29. HERRERA FC: Inhibition of lithium transport across toad
bladder by amiloride. Am J Physiol 222:499-502, 1972
30. LEBLANC G: The mechanism of lithium accumulation in the
isolated frog skin epithelium. Pfluegers Arch 337:1—18,
1972
31. REINACH PS, CANDIA OA, SIEGAL GJ: Lithium transport
across isolated frog skin epithelium. J Membr Biol 25:75-
92, 1975
32. BENTLEY PJ, WASSERMAN A: The effects of lithium on the
permeability of an epithelial membrane, the toad urinary
bladder. Biochim Biophys Acta 266:285-292, 1972
33. SINGER I, FRANKO EA: Lithium-induced ADH resistance
in toad urinary bladders. Kidney mt 3:151-159, 1973
34. MILLER PD, DUBOVSKY SL, MCDONALD KM, KATZ FH,
ROBERTSON GL, SCHRIER RW: Central, renal and adrenal
effects of lithium in man. Am J Med 66:797—803, 1979
35. KIERKEGAARD-HANSEN A, PEDERSEN EB, DARLING S,
AMDISEN A: Plasma renin activity during lithium treatment
of patients. ml Pharmacopsychiatry 12:49-53, 1977
36. PEDERSEN EB, AMDISEN A, DARLING S: Plasma aldoste-
rone and magnesium in serum and urine during lithium
treatment. ml Pharmacopsychiatry 12:80-85, 1977
37. THOMSEN K, JENSEN J, OLESEN OV: Effect of prolonged
lithium ingestion on the response to mineralocorticoids in
rats. J Pharm Exp Ther 196:463-468, 1976
38. Cox M, SINGER I: Lithium-induced inhibition of aldoste-
rone-stimulated Na+ transport in the toad urinary bladder.
C/in Res 26:541A, 1978
39. Cox M, SINGER!: Lithium-induced natriuresis, in Lithium:
Controversies and Unresolved Issues, edited by COOPER
TB, GERSHON 5, KLINE NS, ScHou M, Amsterdam, Ex-
cerpta Medica, 1979, p. 645
40. THOMSEN K, SCHOU M: Renal lithium excretion in man.
Am J Physiol 215:823—827, 1968
41. BLEIwEI5s H: Salt supplements with lithium. Lancet 1:416,
1970
42. DEMERS R, HENINGER G: Sodium intake and lithium treat-
ment in mania. Am J Psychiatry 128:132-136, 1971
43. GEISLER A, ScHou M, THOMSEN K: Renal lithium elimina-
tion in manic-depressive patients. Initial excretion and
clearance. Pharmakopsychiatr Neuropsychopharmakol
4:149—155, 1971
44. THOMSEN K, Scuou M: The effect of prolonged adminis-
tration of hydrochlorothiazide on the renal lithium clear-
ance and the urine flow of ordinary rats and rats with diabe-
tes insipidus. Pharmakopsychiatr Neuropsychopharmakol
6:264-269, 1973
45. PETERSEN V, HVIDT 5, THOMSEN K, Sdllou M: Effect of
prolonged thiazide treatment on renal lithium clearance. Br
MedJ 3:143-145, 1974
46. STEELE TH, DUDGEON KL: Reabsorption of lithium and
phosphate by the rat kidney: Role of parathyroids. Kidney
mt 5:196-203, 1974
47. STEELE TH, MANUEL MA, NEWTOWN M, BONER G: Renal
lithium reabsorption in man: Physiologic and pharmacolog-
ic determinants. Am J Med Sci 269:349—363, 1975
48. STEELE TH, DUDGEON KL, LARMORE CK: Pharmacolo-
gical characterization of lithium reabsorption in the rat. J
Pharmacol Exp Ther 196:188-193, 1976
49. THOMSEN K, OLE5EN OV: Precipitating factors and renal
mechanisms in lithium intoxication. Gen Pharmacol 9:85-
89, 1978
50. THOMSEN K, OLESEN OV: Long-term lithium administra-
tion to rats. Lithium and sodium dosage and administra-
tion, avoidance of intoxication, polyuric control rats. ml
Pharmacopsychiatry 9:118—124, 1974
51. JENSEN J, THOMSEN K, OLESEN OV: Current determina-
tion of lithium-induced minimum sodium requirement in
rats. Psychopharmacologie 45:295-299, 1976
52. CORCORAN AC, TAYLOR RD, PAGE IH: Lithium poisoning
from the use of salt substitutes. JAMA 139:685—688, 1949
53. HANLON LW, ROMAINE M, GILROY FJ, DIETRICK SE:
Lithium chloride as a substitute for sodium chloride in the
diet. JAMA 139:688-692, 1949
54. SCHOU M: Pharmacology and toxicology of lithium. Annu
Rev Pharmacol Toxicol 16:23 1-243, 1976
55. LEVY ST, FORREST JN JR, HENINGER GR: Lithium-in-
duced diabetes insipidus: Manic symptoms, brain and elec-
trolyte correlates, and chlorothiazide treatment. Am J Psy-
chiatry 130:1014—1018, 1973
56. HURTIG H, DYSON W: Lithium toxicity enhanced by diuret-
ics. N Engi J Med 290:748-749, 1974
57. MACFIE AC: Lithium poisoning precipitated by diuretics.
BrMedJ 1:516, 1975
58. MACNEIL S, JENNINGS G, EASTWOOD PR, PASCHALIS C,
JENNER FA: Lithium and the anti-diuretic hormone. Br J
C/in Pharmacol 3:305-3 13, 1976
59. TONKS CM: Lithium-intoxication induced by dieting and
saunas. Br MedJ 2:1396-1397, 1977
60. HIMMELHOCH JM, FORREST J, NEIL JF, DETRE TP: Thia-
zide-lithium synergy in refractory mood swings. Am J
Psychiatry 134:149—152, 1977
61. HIMMELHOCH JM, POUST RI, MALLINGER AG, HANIN I,
NEIL JF: Adjustment of lithium dose during lithium-chloro-
thiazide therapy. C/in Pharmacol Ther 22:225—227, 1977
62. SOLOMON K: Combined use of lithium and diuretics. South
MedJ 71:1098—1104, 1978
63. SCHOU M, BAASTRUP PC, GROF P, WEI5 P, ANGST J: Phar-
macological and clinical problems of lithium prophylaxis.
BrJPsychiatry 116:615—619, 1970
64. WILLIAMS WO, GYORY AZ: Aspects of the use of lithium
for the non-psychiatrist. Aust NZ J Med 6:233-242, 1976
65. MARINI JL, SHEARD MH: Sustained-release lithium car-
bonate in a double-blind study: serum lithium levels, side
effects, and placebo response. J C/in Pharmacol 16:276-
283, 1976
66. PADFIELD PL, PARK SJ, MORTON JJ, BRAIDWOOD AE:
Plasma levels of antidiuretic hormone in patients receiving
prolonged lithium therapy. Br J Psychiatry 130:144-147,
1977
67. BAYLIS PH, HEATH DA: Water disturbances in patients
treated with oral lithium carbonate. Ann Intern Med
88:607—609, 1978
68. Cox M, SINGER I: Lithium and water metabolism. Am J
Med 59:153—157, 1975
386 Nephrology Forum
69. SMITH DF, BALAGURA S, LUBRAN M: Antidotal thirst: a
response to intoxication. Science 167:297—298, 1970
70. SMITH DF, BAIAGURA S: Sodium appetite in rats given
lithium. Life Sci 11:1021—1029, 1972
71. MISKIND MH, GREENSPAN RE, BAY WH, FERRIS TF:
Studies on lithium-induced polyuria. Clin Res 25:596A,
1977
72. PADFIELD PL, MORTON JJ, LINDOP GBM, TIMBURY GC:
Lithium-induced nephrogenic diabetes insipidus; changes
in plasma vasopressin and angiotensin-Il. Clin Nephrol
3:220—224, 1975
73. TORP-PEDERSEN C, THORN NA: Acute effects of lithium on
the action and release of antidiuretic hormone in rats. Acta
Endocrinol (Copenh) 73:665—671, 1973
74. THOMSEN K: Renal elimination of lithium in rats with lith-
ium intoxication. J Pharmacol Exp Ther 199:483-489, 1976
75. CHRISTENSEN S: Acute and chronic effects of vasopressin
in rats with lithium polyuria. Ada Pharmacol Toxicol (Go-
penh) 38:241—253, 1976
76, CHRISTENSEN S: Effect of antidiuretic drugs in rats with
lithium-induced polyuria. Acta Pharmacol Toxicol (Co-
penh) 38:81—89, 1976
77. CHRISTENSEN S. GEISLER A: Antidiuretic and urinary cy-
clic AMP response of vasopressin in normal rats and in rats
with lithium-polyuria. Ada Pharmacol Toxicol (Copenh)
40:447—454, 1977
78. DOUSA TP: Interaction of lithium with vasopressin-sensi-
tive cyclic AMP system of human renal medulla. Endocri-
nology 95:1359—1366, 1974
79. FORREST iN: Lithium-induced polyuria: Cellular mecha-
nisms and response to diuretics, in Lithium: Controversies
and Unresolved issues, edited by COOPER TB, GERSHON 5,
KLINE NS, Scnou M, Amsterdam, Excerpta Medica,
1979, p. 632
80. RoscoE JM, GOLDSTEIN MB, HALPERIN ML, WILSON DR,
STINEBAUGH BJ: Lithium-induced impairment of urine
acidification. Kidney mt 9:344-350, 1976
81. NASCIMENTO L, RADEMACHER DR. HAMBURGER R, AR-
RUDA JAL, KURTZMAN NA: On the mechanism of lithium-
induced renal tubular acidosis, J Lab C/in Med 89:455-462,
1977
82. PEREZ GO, OSTER JR. VAAMONDE CA: Incomplete syn-
drome of renal tubular acidosis induced by lithium carbon-
ate. J Lab C/in Med 86:386-394, 1975
83. PEREZ GO, OSTER JR, SONNEBORN RE, MAGRINAT G,
VAAMONDE CA: Urinary carbon dioxide tension in lithium
carbonate-treated patients. J Pharmacol Exp Ther 201:456-
462, 1977
84. SINGER I, Cox M: Lithium-induced renal tubular acidosis,
in Lithium:Controversies and Unresolved Issues, edited by
COOPER TB, GERSHON S, KLINE NS, SCHOU M, Amster-
dam, Excerpta Medica, 1979, p. 642
85. MEDLOCK TR, VON HARTITZSCH B, FERRIS SA, SPARGO B,
WILSON CB: Lithium-induced nephrotic syndrome. Absi
9th Annu Mtg Am Soc Nephrol, Washington, DC, 1976, p.
61
86. HAFNER H, HöFFLER D, SEIDL H, FRIEDRICH 0: Renal
toxicity of lithium in therapeutic doses. Pharmakopsychiatr
Neuropsychopharmakol 11:157—163, 1978
87. RICHMAN AV, MASCO HL, RIFKIN SI, ACHARYA MK:
Minimal-change disease and nephrotic syndrome associat-
ed with lithium therapy. Ann Intern Med 92:70-72, 1980
88. SCHOU M: Lithium studies. 1. Toxicity. Acta Pharmacol
Toxicol (Copenh) 15:70—84, 1958
89. EVAN AP, OLLERICH DA: The effect of lithium carbonate
on the structure of the rat kidney. Am J Anat 134:97—106,
1972
90. LAVENDER S, BROWN JN, BERRILL WT: Acute renal fail-
ure and lithium intoxication. Postgrad Med J 49:277-279,
1973
91. CHAPMAN AJ, LEWIS G: latrogenic lithium poisoning: A
case report with necropsy findings. Oklahoma State Med
Assoc J 65:491—494, 1972
92. LINDOP GBM, PADFIELD PL: The renal pathology in a case
of lithium-induced diabetes inSipidus. J Clin Pathol 28:472-
475, 1975
93. BURROWS GD, DAVIES B, KINCAID-SMITH P: Unique tubu-
lar lesion after lithium. Lancet 1:13 10, 1978
94. SCHOU M, AMDISEN A, TRAP-JENSEN J: Lithium poison-
ing. Am J Psychiatry 125:520—527, 1968
95. DIAS N, HOCKEN AG: Oliguric renal failure complicating
lithium carbonate therapy. Nephron 10:246—249, 1972
96. HESTBECH J, HANSEN HE, AMDISEN A, OLSEN S: Chronic
renal lesions following long-term treatment with lithium.
Kidney tnt 12:205—213, 1977
97. HANSEN HE, HESTBECH J, SORENSEN JL, NORGAARD K,
HEILSKOV J, AMDISEN A: Chronic interstitial nephropathy
in patients on long-term lithium treatment. Quart J Med
48:577—591, 1979
98. RAFAELSEN OJ, BOL WIG TG, LADEFOIED J, BRUN C: Kid-
ney function and morphology in long-term lithium treat-
ment, in Lithium: Controversies and Unresolved Issues,
edited by COOPER TB, GERSHON 5, KLINE NS, SCHOU M,
Amsterdam, Excerpta Medica, 1979, p. 578
99. KINCAID-SMITH P, BURROWS GD, DAVIES BM, H0LwILL
B, WALTER M, WALKER RG: Renal biopsy findings in lith-
ium and prelithium patients. Lancet 2:700-701, 1979
100. SIMON NM, GARISER E, ARIEFF AJ: Persistent nephrogenic
diabetes insipidus after lithium carbonate. Ann Intern Med
86:446—447, 1977
101. EPSTEIN FH: Disturbances in renal concentrating ability, in
Disturbances in Body Fluid Osmolality, edited by AN-
DREOLI TE, GRANTHAM JJ, RECTOR FC, American Physio-
logical Society, 1977, p. 255
102. BUCHT G, WAHLIN A: Impairment of renal concentrating
capacity by lithium. Lancet 1:778—779, 1978
103. PRICE TRP, BEISSWENGER PJ: Lithium and diabetes insip-
idus. Ann Intern Med 88:576—577, 1978
104. WAGNER B: Lithium and the kidney/Lithium poisoning, in
Lithium: Controversies and Unresolved Issues, edited by
COOPER TB, GERSHON S. KLINE NS, SCHOU M, Amster-
dam, Excerpta Medica, 1979, pp. 668
105. VESTERGAARD P, AMDISEN A, HANSEN HE, SCHOU M:
Lithium treatment and kidney function. A survey of 237
patients in long-term treatment. Acta Psychiatr Scand
60:504-520, 1979
106. HALLGREN R, ALM P0, HELLSING K: Renal function in
patients on lithium treatment. Br J Psychiatry 135:22—27,
1979
107. HULLIN RP, COLEY VP, BIRCH NJ, THOMAS TH, MORGAN
DB: Renal function after long-term treatment with lithium.
BrMedJ 1:1457-1459, 1979
108. DONKER AiM, PRINS E, MEIJER 5, SLUITER WJ, VAN BER-
KESTIJN JWBM, DOLS LCW: A renal function study in 30
patients on long-term lithium therapy. C/in Nephrol 12:254-
262, 1979
109. MULLER-OERLINGHAUSEN B, DRESCHER K: Time course
of clinical-chemical parameters under long-term lithium
Lithium and the kidney 387
treatment. ml i Gun Pharmacol Biopharm 17:228-235, 112. HESTBECH J, OLESEN OV, THOMSEN K: Lithium-induced
1979 focal interstitial fibrosis in the rat kidney. Ada Pathol Mi-
crobiol Scand 86:195-197, 1978
110. COLT EWD, IGEL G, FIEVE RR, DUNNER DL: Lithium-as- 113. BIRCH NJ: A note on animal and human studies of possible
sociated nephropathy. Am J Psychiatry 136:1098-1099, kidney damage caused by lithium, in Lithium in Medical
1979 Practice, edited by JOHNSON FN, JOHNSON S, Baltimore,
University Park Press, 1978, pp. 265
111. KINCAID-SMITH P: Nephrology Forum: Analgesic abuse 114. HESTBECH J, AURELI M: Lithium-induced uremia. Lancet
and the kidney. Kidney mt 17:250-260, 1980 1:212—2 13, 1979
